Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide, Interferon +/- Octreotide in Unresectable Hepatocellular Carcinoma
NCT00250796Phase 2Completed
- Sponsor
- The University of New Mexico
- Start
- Sep 2000
- Primary completion
- Jan 2006
- Modality
- Cytokines & Interferons, Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide, interferon alfa, octreotide in hepatocellular carcinoma (HCC), sponsored by The University of New Mexico. Started Sep 2000; status: completed.
02
Drugs
thalidomideinterferon alfaoctreotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00250796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00250796.